Last updated on June 2020

Evaluation of Efficacy Safety and Tolerability of Aldafermin in a Phase 2b Randomized Double-blind Placebo-controlled Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

Brief description of study

This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.

Clinical Study Identifier: NCT03912532

Find a site near you

Start Over

NGM Clinical Study Site

Lakewood Ranch, FL United States
  Connect »

NGM Clinical Study Site

Sarasota, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.